Program
resmetirom
Also written as “Resmetirom”, “MGL-3196” and “VIA-3196”.
Its studies are mostly in Non-alcoholic Fatty Liver Disease · Fatty Liver · Liver Diseases · Fibrosis · Liver Cirrhosis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Madrigal Pharmaceuticals | 207 open or running | phase 4since Aug 25, 2026 | Jun 2, 2011 | Dec 2026phase 3 · NCT05500222 |
| Nabiqasim Industries (Pvt) | 11 open or running | phase 4since Nov 18, 2025 | Nov 18, 2025 | none ahead |
| Sagimet Biosciences | 10 open or running | phase 1since Oct 8, 2025 | Oct 8, 2025 | none ahead |
Also a collaborator on its studies: celerion.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Jun 2, 2011.
- Jan 22, 2018Phase 1 study in HealthyMadrigal Pharmaceuticals · NCT03413124 · 16 enrolled · United States
- Mar 26, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT03900429 · 1,759 enrolled · United States, Australia, Austria and more
- Dec 11, 2019Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04197479 · 1,343 enrolled · United States, Puerto Rico
- Oct 22, 2020Phase 1 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04643795 · 87 enrolled · United States
- Dec 10, 20202 phase 1 studies in HealthyMadrigal Pharmaceuticals · NCT04671069, NCT04671056
- Jun 18, 2021Phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04951219 · 810 enrolled · United States, Puerto Rico
- Aug 11, 2022Phase 3 study in Liver CirrhosisMadrigal Pharmaceuticals · NCT05500222 · 845 enrolled · United States, Belgium, Canada and more
- Apr 30, 2024Phase 1 study in Renal InsufficiencyMadrigal Pharmaceuticals · NCT06397872 · 28 enrolled · United States
- Oct 8, 2025Sagimet Biosciences's first study: phase 1 study in HealthyNew to Sagimet BiosciencesSagimet Biosciences · NCT07216313 · 40 enrolled · United States
- Nov 18, 2025Nabiqasim Industries (Pvt)'s first study: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisNew to Nabiqasim Industries (Pvt)Nabiqasim Industries (Pvt) · NCT07249788 · 165 planned · Pakistan
- Jan 7, 2026Phase 2 study in FibrosisMadrigal Pharmaceuticals · NCT07335601 · 120 planned · United States, Canada
- Aug 10, 2026Phase 2 study in Liver DiseasesMadrigal Pharmaceuticals · NCT07763015 · 61 planned · United States
- Aug 25, 2026Phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07848191 · 150 planned · United States
- Aug 25, 2026Phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07830758 · 90 planned · United States
Ahead
- Dec 2026Primary completion: phase 3 study in Liver CirrhosisMadrigal Pharmaceuticals · NCT05500222
- Mar 2027Primary completion: phase 3 study in Non-alcoholic Fatty Liver DiseaseMadrigal Pharmaceuticals · NCT04951219
- Nov 2027Primary completion: phase 4 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07848191
- Nov 2027Primary completion: phase 1 study in MASH - Metabolic Dysfunction-Associated SteatohepatitisMadrigal Pharmaceuticals · NCT07830758
TargetBeta
“Thyroid hormone receptor beta-1 agonist”ChEMBL 37, by rule
Other programs on THRB
Studies
All 22 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07848191MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States | 4 | Recruiting | Madrigal Pharmaceuticals | Nov 2027 | 150 |
| NCT07830758MASH - Metabolic Dysfunction-Associated Steatohepatitis · United States | 1 | Recruiting | Madrigal Pharmaceuticals | Nov 2027 | 90 |
| NCT07763015Liver Diseases · United States | 2 | Recruiting | Madrigal Pharmaceuticals | Jul 2029 | 61 |
| NCT07335601Fibrosis · United States, Canada | 2 | Recruiting | Madrigal Pharmaceuticals | Aug 2028 | 120 |
| NCT07249788MASH - Metabolic Dysfunction-Associated Steatohepatitis · Pakistan | 4 | Recruiting | Nabiqasim Industries (Pvt) | Oct 16, 2026 | 165 |
| NCT07216313Healthy · United States | 1 | Completed | Sagimet Biosciences | Oct 20, 2025 | 40 |
| NCT06397872Renal Insufficiency · United States | 1 | Completed | Madrigal Pharmaceuticals | Sep 16, 2024 | 28 |
| NCT05500222Liver Cirrhosis · United States, Belgium, Canada and more | 3 | Active, not recruiting | Madrigal Pharmaceuticals | Dec 2026 | 845 |
| NCT04951219Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 3 | Active, not recruiting | Madrigal Pharmaceuticals | Mar 2027 | 810 |
| NCT04671069Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Aug 30, 2019 | 20 |
| NCT04671056Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Dec 11, 2018 | 16 |
| NCT04643795Non-alcoholic Fatty Liver Disease · United States | 1 | Completed | Madrigal Pharmaceuticals | Aug 4, 2021 | 87 |
| NCT04197479Non-alcoholic Fatty Liver Disease · United States, Puerto Rico | 3 | Completed | Madrigal Pharmaceuticals | Jan 6, 2023 | 1,343 |
| NCT03900429Non-alcoholic Fatty Liver Disease · United States, Australia, Austria and more | 3 | Active, not recruiting | Madrigal Pharmaceuticals | Jan 2028 | 1,759 |
| NCT03413124Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Feb 17, 2018 | 16 |
| NCT03220165Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Sep 3, 2017 | 8 |
| NCT03038022Heterozygous Familial Hypercholesterolemia · Denmark, Netherlands, Norway | 2 | Completed | Madrigal Pharmaceuticals | Jan 15, 2018 | 116 |
| NCT02912260Non-alcoholic Fatty Liver Disease · United States | 2 | Completed | Madrigal Pharmaceuticals | Oct 25, 2017 | 125 |
| NCT02749578Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | May 2016 | 14 |
| NCT02542969Healthy · United States | 1 | Completed | Madrigal Pharmaceuticals | Oct 2015 | 25 |
| NCT01519531Drug Safety · United States | 1 | Completed | Madrigal Pharmaceuticals | Nov 2012 | 48 |
| NCT01367873Drug Safety · United States | 1 | Completed | Madrigal Pharmaceuticals | Oct 2011 | 72 |
How it is read
Names in the registry
- “Resmetirom”, 9 entries
- “MGL-3196”, 8 entries
- “VIA-3196”, 2 entries
- “Rezdiffra”, 1 entry
- “MGL-3196 (resmetirom)”, 1 entry
Conditions, from the studies’ own filings
- Non-alcoholic Fatty Liver Disease, 5 studies
- Fatty Liver, 3 studies
- Liver Diseases, 1 study
- Fibrosis, 1 study
- Liver Cirrhosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.